Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia in Shanghai, China. Issue 10 (2nd June 2020) - Shi, Xiudong
Abstract: The aim of our study was to evaluate the therapeutic effect of antiviral drugs on coronavirus disease 2019 (COVID‐19) pneumonia. Patients confirmed with COVID‐19 pneumonia were enrolled and divided into seven groups according to the treatment option. Information including age, sex, and duration from illness onset to admission, clinical manifestations, and laboratory data at admission, and length of hospital stay were evaluated. The chest computed tomography (CT) imaging obtained at admission and after a 5‐day treatment cycle were assessed. The clinical symptoms and laboratory tests at discharge were also assessed. At admission, no significant differences were found among the groups, including the duration from illness onset to admission, clinical symptoms, and main laboratory results. No significant differences were found among the groups in terms of the proportion of patients with pneumonia resolution ( P = .151) after treatment or the length of hospital stay ( P = .116). At discharge, 7 of 184 (4%) patients had a mild cough while their other symptoms had disappeared, and the proportion of patients with abnormal liver function and with increased leukocytes, neutrophils or erythrocyte sedimentation rate among the 184 patients were close to those at admission. According to the results, the inclusion of antiviral drugs in therapeutic regimens based on symptomatic treatment had no significant additional impact on the improvement in COVID‐19 patients. In addition, the results of chest CT imaging, clinical manifestations, and laboratory tests at discharge were not completely consistent. Highlights: Therapeutic effect of commercial antiviral drugs on COVID‐19 pneumonia.